EUCTR2004-001301-10-IT进行中（未招募）不适用
A PHASE II PROSPECTIVE, RANDOMIZED, DOUBLE-MASKED, SHAM-CONTROLLED, DOSE-RANGING, MULTI-CENTER TRIAL TO ASSESS THE EFFECT OF PEGAPTANIB SODIUM ON FOVEAL THICKENING IN PATIENTS WITH EXUDATIVE SUBFOVEAL AGE-RELATED MACULAR DEGENERATION (AMD)
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- PFIZER
- 入组人数
- 135
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- 未提供
研究者
相似试验
进行中（未招募）
1 期
Study of Intravitreal KSI-301 in Patients With Neovascular (Wet) Agerelated Macular Degeneratioeovascular (Wet) Age-related Macular DegenerationMedDRA version: 20.1Level: LLTClassification code 10067791Term: Wet macular degenerationSystem Organ Class: 10015919 - Eye disordersMedDRA version: 20.0Level: SOCClassification code 10015919Term: Eye disordersSystem Organ Class: 10015919 - Eye disordersMedDRA version: 20.0Level: PTClassification code 10071129Term: Neovascular age-related macular degenerationSystem Organ Class: 10015919 - Eye disordersEUCTR2018-003428-35-ITKodiak Sciences Inc.368
进行中（未招募）
1 期
Study of Intravitreal KSI-301 in Patients With Neovascular (Wet) Age-related Macular DegeneratioEUCTR2018-003428-35-GBKodiak Sciences Inc.368
进行中（未招募）
1 期
Study of Intravitreal KSI-301 in Patients With Neovascular (Wet) Age-related Macular DegeneratioEUCTR2018-003428-35-ESKodiak Sciences Inc.368
Unknown
2 期
To study the efficacy and safety of Nexagon�® (NEXAGON) applied topically in subjects with corneal persistent epithelial defects (PED) resulting from severe ocular chemical and/or thermal injuries.CTRI/2019/08/020943OcuNexus Therapeutics Inc33
进行中（未招募）
1 期
Clinical trial to evaluate the safety of a vaginal gel containing 0.005% of estriol, in hormone receptor-positive women in menopause with early stage breast cancer in treatment with aromatase inhibitorIn postmenopausal hormone receptor positive breast cancer, treatment with aromatase inhibitors is the most effective and well-studied therapy. Lack of adherence is common due to the side-effectsvaginal dryness and vaginal atrophy. The study will explore the safety of 0.005% estriol vaginal gel in the oncological context, to demostrate that the gel is a safe option to treat the vaginal atrophy caused by AIs, without a significant decline in gonadotropin or increase in systemic estrogen levelsEUCTR2014-004517-84-ESITF Research Pharma S.L.61